Implantable Cardioverter Defibrillator Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia

Overview

Información sobre este estudio

The purpose of this study is to compare the rate of arrhythmia-induced events between paediatric Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) patients with and without implantable cardioverter defibrillator (ICDs), and to determine the quality of life and psychosocial functioning of paediatric CPVT patients with and without ICDs.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • A paediatric patient who has received a diagnosis of CPVT, and has experienced a cardiac arrest/appropriate ICD shock:
  • A diagnosis of CPVT is typically made in the presence of a structurally normal heart, normal QTc interval on resting ECG, and a clinical phenotype of exertional or emotional syncope or cardiac arrest and at least one of the following:
    • Unexplained exercise or catecholamine-induced bidirectional VT or polymorphic ventricular premature beats or VT;
    • Identification of a heterozygous pathogenic/likely pathogenic variant or biallelic pathogenic/likely pathogenic variants in a gene known to be associated with CPVT.
  • Aged 5-19 years old inclusive at time of consent.
  • A patient that is already enrolled in the Paediatric CPVT Registry.
  • Fluent in English (all questionnaires are written in English), or recruited at a site where the questionnaires are available in an appropriate language.

Exclusion Criteria:

  • Parents or patients unable/unwilling to provide informed consent or assent, respectively.
  • Significant co-morbid condition not directly related to a complication of CPVT.
  • Individuals (including parents) who are not fluent in written/spoken English.
  • Intellectual disability or neurodevelopmental disabilities that would interfere with the patient’s ability to assent and complete questionnaires.
  • Non-CPVT related significant life events within the preceding 6 months (e.g., serious illness [personal or family], death of family or friends, divorce/separation).

Eligibility last updated 6/27/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Michael Ackerman, M.D., Ph.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Carla Haglund-Turnquist

(507) 284-8900

HaglundTurnquist.Carla@mayo.edu

More information

Publicaciones

Publications are currently not available